Skip to Content
You are currently on the new version of our website. Access the old version .

39 Results Found

  • Article
  • Open Access
456 Views
17 Pages

Early Recognition of Patients with Neuronopathic Forms of Mucopolysaccharidosis Type II in Clinical Practice

  • Natalia V. Buchinskaia,
  • Ekaterina Yu. Zakharova,
  • Anastasia O. Vechkasova,
  • Irina A. Chikova and ,
  • Nato D. Vashakmadze,
  • Leyla S. Namazova-Baranova,
  • Dmitry O. Ivanov,
  • Sergei I. Kutsev and
  • Mikhail M. Kostik
  • + 4 authors+ 0 author

30 September 2026

Background: Mucopolysaccharidosis type II (MPS II) is a progressive, rare, X-linked inherited disease with multi-organ involvement and a restricted life expectancy. The disease has two main forms: neuronopathic (severe) and non-neuronopathic (attenua...

(This article belongs to the Special Issue Mucopolysaccharidoses: From Disease Mechanisms to Emerging Therapies)
  • Review
  • Open Access
27 Citations
6,684 Views
16 Pages

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

  • Hiroyuki Sonoda,
  • Kenichi Takahashi,
  • Kohtaro Minami,
  • Toru Hirato and ,
  • Tatsuyoshi Yamamoto,
  • Sairei So,
  • Kazunori Tanizawa,
  • Mathias Schmidt and
  • Yuji Sato
  • + 4 authors+ 0 author

Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervo...

(This article belongs to the Special Issue Advanced Blood-Brain Barrier Drug Delivery)
  • Review
  • Open Access
1 Citations
1,100 Views
23 Pages

Gaucher disease is a prototypical lysosomal sphingolipid storage disorder caused by pathogenic variants in GBA1, resulting in glucocerebrosidase deficiency and accumulation of bioactive lipids, including glucosylceramide and glucosylsphingosine (lyso...

(This article belongs to the Special Issue Sphingolipids: Health and Disease)
  • Article
  • Open Access
46 Citations
8,963 Views
15 Pages

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data

  • Roberto Giugliani,
  • Ana Maria Martins,
  • Torayuki Okuyama,
  • Yoshikatsu Eto and ,
  • Norio Sakai,
  • Kimitoshi Nakamura,
  • Hideto Morimoto,
  • Kohtaro Minami,
  • Tatsuyoshi Yamamoto and
  • Yuji Sato
  • + 11 authors+ 6 authors

10 October 2021

Enzyme replacement therapy (ERT) improves somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood–brain barrier (BBB), ERT is ineffective against the progressive neurodegenerat...

(This article belongs to the Special Issue Genetic and Metabolic Molecular Research of Lysosomal Storage Disease 2.0)
  • Article
  • Open Access
1 Citations
2,802 Views
17 Pages

15 December 2024

Mucopolysaccharidosis (MPS) comprises a group of inherited metabolic diseases. Each MPS type is caused by a deficiency in the activity of one kind of enzymes involved in glycosaminoglycan (GAG) degradation, resulting from the presence of pathogenic v...

(This article belongs to the Collection Feature Papers in Molecular Genetics and Genomics)
  • Review
  • Open Access
16 Citations
8,468 Views
17 Pages

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art

  • María José de Castro,
  • Mireia del Toro,
  • Roberto Giugliani and
  • María Luz Couce

25 August 2021

The need for long-lasting and transformative therapies for mucopolysaccharidoses (MPS) cannot be understated. Currently, many forms of MPS lack a specific treatment and in other cases available therapies, such as enzyme replacement therapy (ERT), do...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management 2.0)
  • Article
  • Open Access
30 Citations
6,348 Views
23 Pages

Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease

  • Or Cabasso,
  • Sumit Paul,
  • Orly Dorot,
  • Gali Maor and ,
  • Olga Krivoruk,
  • Metsada Pasmanik-Chor,
  • Mina Mirzaian,
  • Maria Ferraz,
  • Johannes Aerts and
  • Mia Horowitz
  • + 5 authors+ 0 author

9 September 2019

Gaucher disease (GD) results from mutations in the GBA1 gene, which encodes lysosomal glucocerebrosidase (GCase). The large number of mutations known to date in the gene lead to a heterogeneous disorder, which is divided into a non-neuronopathic, typ...

(This article belongs to the Special Issue Lysosomal Storage Disorders: Causes, Symptoms, Diagnosis, and Treatment)
  • Article
  • Open Access
4 Citations
6,310 Views
23 Pages

Mucopolysaccharidoses (MPS) are a group of diseases caused by mutations in genes encoding lysosomal enzymes that catalyze reactions of glycosaminoglycan (GAG) degradation. As a result, GAGs accumulate in lysosomes, impairing the proper functioning of...

(This article belongs to the Special Issue Complex Molecular Mechanism of Monogenic Diseases 2.0)
  • Review
  • Open Access
481 Views
15 Pages

19 September 2026

Neuronopathic lysosomal storage disorders remain difficult to treat because conventional enzyme replacement therapies generally do not reach therapeutically meaningful concentrations in the central nervous system. Miglustat (1,5-(butylimino)-1,5-dide...

(This article belongs to the Special Issue Genetic and Metabolic Molecular Research of Lysosomal Storage Disease: 5th Edition)
  • Article
  • Open Access
13 Citations
4,430 Views
9 Pages

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses

  • Galina Baydakova,
  • Alex Ilyushkina,
  • Lidia Gaffke,
  • Karolina Pierzynowska and ,
  • Igor Bychkov,
  • Agnieszka Ługowska,
  • Grzegorz Wegrzyn,
  • Anna Tylki-Szymanska and
  • Ekaterina Zakharova
  • + 4 authors+ 0 author

Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders associated with impaired glycosaminoglycans (GAGs) catabolism. In MPS I, II, III, and VII, heparan sulfate (HS) cannot be degraded because of the lack of sufficient activity of t...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management)
  • Feature Paper
  • Review
  • Open Access
73 Citations
13,314 Views
11 Pages

Gaucher disease, the most common lysosomal storage disorder, is due to a deficiency in the enzyme glucocerebrosidase. This leads to the accumulation of its normal substrate, glucocerebroside, in tissue macrophages, affecting the hematological, viscer...

(This article belongs to the Collection Lysosomal Storage Diseases)
  • Article
  • Open Access
31 Citations
9,552 Views
20 Pages

Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients

  • Akhil Bhalla,
  • Ritesh Ravi,
  • Meng Fang,
  • Annie Arguello and ,
  • Sonnet S. Davis,
  • Chi-Lu Chiu,
  • Jessica R. Blumenfeld,
  • Hoang N. Nguyen,
  • Timothy K. Earr and
  • Maria L. Escolar
  • + 14 authors+ 9 authors

Mucopolysaccharidosis type II is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS) and characterized by the accumulation of the primary storage substrate, glycosaminoglycans (GAGs). Understanding central nervous syste...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management)
  • Article
  • Open Access
2 Citations
2,128 Views
12 Pages

Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease

  • Patryk Lipiński,
  • Dariusz Rokicki,
  • Karolina Chwiałkowska,
  • Michał Ciborowski and ,
  • Joanna Godzień,
  • Aleksandra Jezela-Stanek,
  • Urszula Korotko,
  • Mirosław Kwaśniewski,
  • Magdalena Niemira and
  • Anna Tylki-Szymańska
  • + 7 authors+ 2 authors

16 March 2026

Background: Gaucher disease (GD) is a lysosomal storage disorder caused by deficiency of β-glucocerebrosidase, leading to accumulation of glucocerebroside in lysosomes. Type 1 GD is most commonly associated with the N370S mutation and lacks neur...

(This article belongs to the Section Physiology and Pathology)
  • Article
  • Open Access
14 Citations
6,846 Views
14 Pages

3 December 2020

Gaucher Disease (GD), which is the most common lysosomal storage disorder, is caused by bi-allelic mutations in GBA1—a gene that encodes the lysosomal hydrolase β-glucocerebrosidase (GCase). The neuronopathic forms of GD (nGD) are characte...

(This article belongs to the Special Issue Lysosomal Storage Disorders: Molecular Basis and Therapeutic Approaches)
  • Review
  • Open Access
7 Citations
5,784 Views
32 Pages

Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review

  • Walla Al-Hertani,
  • Ravi R. Pathak,
  • Obaro Evuarherhe,
  • Gemma Carter and ,
  • Carolyn R. Schaeffer-Koziol,
  • David A. H. Whiteman and
  • Ekaterina Wright
  • + 2 authors+ 0 author

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare, X-linked disorder caused by deficient activity of the enzyme iduronate-2-sulfatase. Signs and symptoms typically emerge at 1.5–4 years of age and may include cognitive impairmen...

(This article belongs to the Section Molecular Endocrinology and Metabolism)
  • Article
  • Open Access
1,224 Views
21 Pages

The c-Abl-RIPK3 Axis Drives Mitochondrial Dysfunction and Impaired Mitophagy in Gaucher Disease Models

  • Cristian M. Lamaizon,
  • Renatta Tironi-Hernández,
  • Nohela B. Arévalo,
  • Sebastián D. Ahumada and ,
  • Daniela A. Gutiérrez,
  • Laura Brito-Fernández,
  • Andrea del Campo,
  • Silvana Zanlungo and
  • Alejandra R. Álvarez
  • + 4 authors+ 0 author

Gaucher disease (GD) is characterized by the accumulation of glucosylceramide within lysosomes due to mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase. Current treatments are ineffective for patients suffering from severe neuro...

(This article belongs to the Special Issue Oxidative Stress in Rare Diseases: Mechanisms, Implications, and Therapeutic Opportunities)
  • Review
  • Open Access
17 Citations
11,001 Views
18 Pages

Advancements in Viral Gene Therapy for Gaucher Disease

  • Akhil Kulkarni,
  • Tiffany Chen,
  • Ellen Sidransky and
  • Tae-Un Han

15 March 2024

Gaucher disease, an autosomal recessively inherited lysosomal storage disorder, results from biallelic mutations in the GBA1 gene resulting in deficient activity of the enzyme glucocerebrosidase. In Gaucher disease, the reduced levels and activity of...

(This article belongs to the Special Issue Genetics and Genomics of Inherited Metabolic Diseases)
  • Review
  • Open Access
8 Citations
2,039 Views
16 Pages

10 February 2026

Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the glucocerebrosidase gene (GBA1), leading to acid β-glucosidase deficiency and the accumulation of glucosylceramide-derived glycosphingolipids. Its three phenotypes (n...

(This article belongs to the Special Issue Gaucher Disease: From Molecular Mechanisms to Treatments)
  • Review
  • Open Access
28 Citations
6,569 Views
11 Pages

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism

  • Makaila L. Furderer,
  • Ellen Hertz,
  • Grisel J. Lopez and
  • Ellen Sidransky

Deficient acid β-glucocerebrosidase activity due to biallelic mutations in GBA1 results in Gaucher disease (GD). Patients with this lysosomal storage disorder exhibit a wide range of associated manifestations, spanning from virtually asymptomati...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
1,381 Views
11 Pages

Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening

  • Yuki Ueda,
  • Shinsuke Hirabayashi,
  • Masayuki Miura,
  • Satoshi Yamada and ,
  • Sachiko Nakakubo,
  • Midori Nakajima,
  • Takeru Goto,
  • Jutaro Abe,
  • Yukayo Terashita and
  • Kiyoshi Egawa
  • + 7 authors+ 2 authors

Enzyme replacement therapy (ERT) for central nervous system symptoms and newborn screening (NBS) is available in Japan for patients with mucopolysaccharidosis type II (MPS II). Of 12 suspected cases identified through the NBS program, 3 patients were...

(This article belongs to the Special Issue Advances in Newborn Screening for Lysosomal Disorders: From Laboratory Screening to Diagnosis)
  • Review
  • Open Access
21 Citations
4,999 Views
7 Pages

30 November 2020

Morquio B disease (MBD) is an autosomal recessive GLB1-gene-related lysosomal storage disease, presenting with a peculiar type of dysostosis multiplex which is also observed in GALNS-related Morquio A disease. MBD may present as pure skeletal phenoty...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management 2.0)
  • Article
  • Open Access
5 Citations
3,621 Views
13 Pages

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy

  • Paweł Dubiela,
  • Paulina Szymańska-Rożek,
  • Andrzej Eljaszewicz,
  • Patryk Lipiński and ,
  • Piotr Hasiński,
  • Dorota Giersz,
  • Alicja Walewska,
  • Marlena Tynecka,
  • Marcin Moniuszko and
  • Anna Tylki-Szymańska
  • + 5 authors+ 0 author

3 April 2023

Gaucher disease (GD) is the most frequent sphingolipidosis, caused by biallelic pathogenic variants in the GBA1 gene encoding for β-glucocerebrosidase (GCase, E.C. 3.2.1.45). The condition is characterized by hepatosplenomegaly, hematological abnorma...

(This article belongs to the Section Molecular Biomarkers)
  • Review
  • Open Access
60 Citations
10,274 Views
23 Pages

Ferroptosis and Its Modulation by Autophagy in Light of the Pathogenesis of Lysosomal Storage Diseases

  • Karolina Pierzynowska,
  • Estera Rintz,
  • Lidia Gaffke and
  • Grzegorz Węgrzyn

10 February 2021

Ferroptosis is one of the recently described types of cell death which is dependent on many factors, including the accumulation of iron and lipid peroxidation. Its induction requires various signaling pathways. Recent discovery of ferroptosis inducti...

(This article belongs to the Special Issue 10th Anniversary of Cells—Advances in Autophagy)
  • Case Report
  • Open Access
1 Citations
2,340 Views
8 Pages

Pediatric Gaucher Disease Type 3 Presenting with Oculomotor Apraxia: A Case Report

  • Margherita Di Costanzo,
  • Nicoletta de Paulis,
  • Giuseppe Cannalire,
  • Nicola Morelli and
  • Giacomo Biasucci

9 August 2024

We report on a 4-year-old boy affected by Gaucher disease (GD) type 3, who presented with splenomegaly and a history of oculomotor apraxia. GD is a rare lysosomal storage disorder caused by glucocerebrosidase deficiency with multi-organ involvement....

(This article belongs to the Section Pediatric Neurology & Neurodevelopmental Disorders)
  • Article
  • Open Access
36 Citations
6,912 Views
18 Pages

Probing the Inhibitor versus Chaperone Properties of sp2-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease

  • Teresa Mena-Barragán,
  • M. Isabel García-Moreno,
  • Alen Sevšek,
  • Tetsuya Okazaki and ,
  • Eiji Nanba,
  • Katsumi Higaki,
  • Nathaniel I. Martin,
  • Roland J. Pieters,
  • José M. García Fernández and
  • Carmen Ortiz Mellet
  • + 5 authors+ 0 author

A series of sp2-iminosugar glycomimetics differing in the reducing or nonreducing character, the configurational pattern (d-gluco or l-ido), the architecture of the glycone skeleton, and the nature of the nonglycone substituent has been synthesized a...

(This article belongs to the Special Issue Glycomimetics: Design, Synthesis and Therapeutic Applications)
  • Article
  • Open Access
10 Citations
4,212 Views
14 Pages

Laryngeal, Tracheal, and Bronchial Disease in the Mucopolysaccharidoses: Endoscopic Study

  • Paulo Pires de Mello,
  • Anneliese Lopes Barth,
  • Danielle de Araujo Torres,
  • Mariana Pires de Mello Valente and
  • Dafne Dain Gandelman Horovitz

Mucopolysaccharidoses (MPS) are genetically determined diseases, leading to a deficiency of enzymes in the glycosaminoglycan (GAG) degradation pathway. The accumulation of GAG occurs in connective tissue in various organs and systems of the body, inc...

(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management)
  • Article
  • Open Access
31 Citations
6,666 Views
14 Pages

Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy

  • Vincenza Gragnaniello,
  • Chiara Cazzorla,
  • Daniela Gueraldi,
  • Andrea Puma and ,
  • Christian Loro,
  • Elena Porcù,
  • Maria Stornaiuolo,
  • Paolo Miglioranza,
  • Leonardo Salviati and
  • Alberto B. Burlina
  • + 6 authors+ 1 author

In the last two decades, the development of high-throughput diagnostic methods and the availability of effective treatments have increased the interest in newborn screening for lysosomal storage disorders. However, long-term follow-up experience is n...

(This article belongs to the Special Issue Neonatal Screening in Europe: On the Brink of a New Era)
  • Review
  • Open Access
12 Citations
5,988 Views
21 Pages

Animal Models for the Study of Gaucher Disease

  • Or Cabasso,
  • Aparna Kuppuramalingam,
  • Lindsey Lelieveld,
  • Martijn Van der Lienden and ,
  • Rolf Boot,
  • Johannes M. Aerts and
  • Mia Horowitz
  • + 2 authors+ 0 author

7 November 2023

In Gaucher disease (GD), a relatively common sphingolipidosis, the mutant lysosomal enzyme acid β-glucocerebrosidase (GCase), encoded by the GBA1 gene, fails to properly hydrolyze the sphingolipid glucosylceramide (GlcCer) in lysosomes, particul...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Communication
  • Open Access
5 Citations
4,541 Views
9 Pages

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease

  • Yishay Weill,
  • Ari Zimran,
  • David Zadok,
  • Lauren M. Wasser and ,
  • Shoshana Revel-Vilk,
  • Joel Hanhart,
  • Tama Dinur,
  • David Arkadir and
  • Michal Becker-Cohen
  • + 4 authors+ 0 author

24 September 2020

Type-1 Gaucher disease (GD1) is considered to be non- neuronopathic however recent evidence of neurological involvement continues to accumulate. There is limited evidence of retinal abnormalities in GD1. The purpose of this study was to evaluate the...

(This article belongs to the Special Issue Pathophysiology, Molecular Mechanism and Therapeutic Strategies of Lysosomal Storage Disorders (LSD))
  • Feature Paper
  • Article
  • Open Access
12 Citations
3,999 Views
10 Pages

iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death

  • Daria Messelodi,
  • Salvatore Nicola Bertuccio,
  • Valentina Indio,
  • Silvia Strocchi and ,
  • Alberto Taddia,
  • Salvatore Serravalle,
  • Jessica Bandini,
  • Annalisa Astolfi and
  • Andrea Pession
  • + 4 authors+ 0 author

21 October 2021

Gaucher disease is a lysosomal storage disorder characterized by β-glucosidase enzyme deficiency and substrate accumulation, especially in cells of the reticuloendothelial system. Typical features of the disease are the unrestrained activation of inf...

(This article belongs to the Special Issue Induced Pluripotent Stem Cells (IPSC) as a Disease Modeling and Drug Development Platform)
  • Article
  • Open Access
16 Citations
7,127 Views
15 Pages

Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease

  • Constanza Bondar,
  • Maximiliano Ormazabal,
  • Andrea Crivaro,
  • Malena Ferreyra-Compagnucci and ,
  • María Victoria Delpino,
  • Paula Adriana Rozenfeld and
  • Juan Marcos Mucci
  • + 2 authors+ 0 author

Gaucher disease (GD) is caused by mutations in the glucosylceramidase β (GBA 1) gene that confer a deficient level of activity of glucocerebrosidase (GCase). This deficiency leads to the accumulation of the glycolipid glucocerebroside in the lysosome...

(This article belongs to the Special Issue Lysosomal Storage Disorders: Novel Concepts, Therapeutic Aspects and Beyond)
  • Article
  • Open Access
5 Citations
3,711 Views
14 Pages

A Brazilian Rare-Disease Center’s Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF

  • Matheus Vernet Machado Bressan Wilke,
  • Gabrielle Dineck Iop,
  • Larissa Faqueti,
  • Layzon Antonio Lemos da Silva and ,
  • Francyne Kubaski,
  • Fabiano O. Poswar,
  • Kristiane Michelin-Tirelli,
  • Dévora Randon,
  • Wyllians Vendramini Borelli and
  • Ida Vanessa D. Schwartz
  • + 6 authors+ 1 author

Gaucher disease (GD, OMIM 230800) is one of the most common lysosomal disorders, being caused by the deficient activity of the enzyme acid β-glucocerebrosidase (Gcase). Three clinical forms of Gaucher’s disease (GD) are classified based on...

(This article belongs to the Special Issue Genetic and Metabolic Molecular Research of Lysosomal Storage Disease 3.0)
  • Article
  • Open Access
19 Citations
4,537 Views
12 Pages

New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases

  • Justyna Spiewak,
  • Ivan Doykov,
  • Apostolos Papandreou,
  • Jenny Hällqvist and ,
  • Philippa Mills,
  • Peter T. Clayton,
  • Paul Gissen,
  • Kevin Mills and
  • Wendy E. Heywood
  • + 4 authors+ 0 author

Dried blood spots (DBSs) biomarkers are convenient for monitoring for specific lysosomal storage diseases (LSDs), but they could have relevance for other LSDs. To determine the specificity and utility of glycosphingolipidoses biomarkers against other...

(This article belongs to the Special Issue Biomarkers in Rare Diseases 3.0)
  • Article
  • Open Access
2,908 Views
9 Pages

Novel Phenotypic Insights into the IDS c.817C>T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts

  • Éliane Beauregard-Lacroix,
  • Caitlin Menello,
  • Madeline Steffensen,
  • Hsiang-Yu Lin and ,
  • Chih-Kuang Chuang,
  • Shuan-Pei Lin and
  • Can Ficicioglu
  • + 2 authors+ 0 author

Mucopolysaccharidosis (MPS) type II, or Hunter syndrome, is an X-linked lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase. Glycosaminoglycan (GAG) accumulation leads to progressive multisystemic involvement, with coarse facia...

(This article belongs to the Special Issue Advances in Newborn Screening for Lysosomal Disorders: From Laboratory Screening to Diagnosis)
  • Review
  • Open Access
2,580 Views
31 Pages

Refining Mouse Models of Gaucher Disease: Advancing Mechanistic Insights, Biomarker Discovery, and Therapeutic Strategies

  • Nima Fattahi,
  • Jiapeng Ruan,
  • Glenn Belinsky,
  • Shu Xing and ,
  • Pramod K. Mistry and
  • Shiny Nair
  • + 1 author+ 0 author

10 December 2025

Gaucher disease (GD), caused by biallelic pathogenic variants in GBA1, has evolved from being understood as a macrophage-restricted lysosomal disorder to a multisystem condition involving neuroinflammation, immune dysregulation, and cell-type-specifi...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
5 Citations
5,461 Views
29 Pages

Neurological Disease Modeling Using Pluripotent and Multipotent Stem Cells: A Key Step towards Understanding and Treating Mucopolysaccharidoses

  • Sofia Carvalho,
  • Juliana Inês Santos,
  • Luciana Moreira,
  • Mariana Gonçalves and ,
  • Hugo David,
  • Liliana Matos,
  • Marisa Encarnação,
  • Sandra Alves and
  • Maria Francisca Coutinho
  • + 4 authors+ 0 author

Despite extensive research, the links between the accumulation of glycosaminoglycans (GAGs) and the clinical features seen in patients suffering from various forms of mucopolysaccharidoses (MPSs) have yet to be further elucidated. This is particularl...

(This article belongs to the Section Cell Biology and Pathology)
  • Article
  • Open Access
1,544 Views
7 Pages

Gaucher’s Disease in Lithuania: Its Diagnosis and Treatment

  • Gražina Kleinotienė,
  • Anna Tylki-Szymanska and
  • Barbara Czartoryska

1 August 2011

Gaucher’s disease is a lysosomal storage disease caused by the lack of beta-glucocerebrosidase enzyme, leading to the accumulation of glucocerebroside. Gaucher’s disease is the most frequent type of sphingolipidosis as well as the most frequent lysos...

  • Article
  • Open Access
44 Citations
6,983 Views
11 Pages

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?

  • Tama Dinur,
  • Peter Bauer,
  • Christian Beetz,
  • Guido Kramp and ,
  • Claudia Cozma,
  • Marius-Ionuț Iurașcu,
  • Michal Becker-Cohen,
  • Majdolen Istaiti,
  • Arndt Rolfs and
  • Shoshana Revel-Vilk
  • + 6 authors+ 1 author

30 January 2022

For years, the gold standard for diagnosing Gaucher disease (GD) has been detecting reduced β-glucocerebrosidase (GCase) activity in peripheral blood cells combined with GBA1 mutation analysis. The use of dried blood spot (DBS) specimens offers...

(This article belongs to the Section Molecular Biology)
  • Article
  • Open Access
15 Citations
4,611 Views
10 Pages

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease

  • Tama Dinur,
  • Peter Bauer,
  • Christian Beetz,
  • Claudia Cozma and ,
  • Michal Becker-Cohen,
  • Majdolen Istaiti,
  • Arndt Rolfs,
  • Volha Skrahina,
  • Ari Zimran and
  • Shoshana Revel-Vilk
  • + 5 authors+ 0 author

15 February 2023

Glucosylsphingosine (lyso-Gb1), the deacylated form of glucocerebroside, was shown to be the most specific and sensitive biomarker for diagnosing Gaucher disease (GD). The aim of this study is to assess the contribution of lyso-Gb1 at the time of dia...

(This article belongs to the Collection Feature Papers in Molecular Pathology, Diagnostics, and Therapeutics)